迪瑞医疗
(300396)
| 流通市值：36.43亿 | | | 总市值：36.46亿 |
| 流通股本：2.72亿 | | | 总股本：2.73亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,217,807,735.16 | 1,175,445,053.92 | 878,270,442.69 | 662,535,125.59 |
| 营业收入 | 1,217,807,735.16 | 1,175,445,053.92 | 878,270,442.69 | 662,535,125.59 |
| 二、营业总成本 | 1,107,954,218.58 | 986,818,603.55 | 715,273,727.92 | 532,151,957.58 |
| 营业成本 | 683,955,656.48 | 665,191,024.53 | 499,767,255.82 | 421,381,170.19 |
| 税金及附加 | 11,490,628.81 | 9,690,305.51 | 5,634,198.65 | 3,509,850.5 |
| 销售费用 | 231,537,434.1 | 177,180,126.68 | 123,253,400.43 | 61,548,750.18 |
| 管理费用 | 56,839,267.07 | 34,301,565.3 | 24,922,488 | 12,424,634.92 |
| 研发费用 | 130,431,565.75 | 95,643,187.59 | 63,079,105.67 | 32,040,993.06 |
| 财务费用 | -6,300,333.63 | 4,812,393.94 | -1,382,720.65 | 1,246,558.73 |
| 其中:利息费用 | 8,736,876.51 | 5,843,826.12 | 3,856,330.98 | 1,893,526.4 |
| 其中:利息收入 | 18,872,358.53 | 5,229,684.7 | 3,918,302.46 | 2,110,974.15 |
| 加:公允价值变动收益 | -185,848.63 | -185,848.63 | -185,848.63 | -327,531.63 |
| 加:投资收益 | 23,607,377.55 | 20,686,292.54 | 15,185,936.95 | 6,240,842.95 |
| 资产处置收益 | 82,446.44 | 0 | 0 | 0 |
| 资产减值损失(新) | -1,085,123.38 | -2,754,655.98 | 129,594.96 | 311,476.51 |
| 信用减值损失(新) | -11,107,671.88 | -11,883,878.16 | -12,719,287.2 | -9,436,027.29 |
| 其他收益 | 22,483,639.93 | 19,617,801.24 | 17,131,702.29 | 14,239,074.57 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 143,648,336.61 | 214,106,161.38 | 182,538,813.14 | 141,411,003.12 |
| 加:营业外收入 | 3,056,183.69 | 448,539.74 | 27,016.42 | 114,046.11 |
| 减:营业外支出 | 1,016,796.37 | 937,650.95 | 742,978.93 | 537,206.44 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 145,687,723.93 | 213,617,050.17 | 181,822,850.63 | 140,987,842.79 |
| 减:所得税费用 | 3,782,718.32 | 21,050,445.45 | 16,589,240.82 | 19,194,365.68 |
| 六、净利润 | 141,905,005.61 | 192,566,604.72 | 165,233,609.81 | 121,793,477.11 |
| 持续经营净利润 | 141,905,005.61 | 192,566,604.72 | 165,233,609.81 | 121,793,477.11 |
| 归属于母公司股东的净利润 | 141,922,552.76 | 192,577,440.82 | 165,242,953.91 | 121,800,597.55 |
| 少数股东损益 | -17,547.15 | -10,836.1 | -9,344.1 | -7,120.44 |
| (一)基本每股收益 | 0.52 | 0.71 | 0.61 | 0.45 |
| (二)稀释每股收益 | 0.52 | 0.71 | 0.61 | 0.45 |
| 八、其他综合收益 | 3,902,996.17 | 867,601.54 | 1,144,923.19 | 542,085.22 |
| 归属于母公司股东的其他综合收益 | 3,903,295.08 | 867,496.48 | 1,146,578.92 | 543,571.52 |
| 九、综合收益总额 | 145,808,001.78 | 193,434,206.26 | 166,378,533 | 122,335,562.33 |
| 归属于母公司股东的综合收益总额 | 145,825,847.84 | 193,444,937.3 | 166,389,532.83 | 122,344,169.07 |
| 归属于少数股东的综合收益总额 | -17,846.06 | -10,731.04 | -10,999.83 | -8,606.74 |
| 公告日期 | 2025-03-29 | 2024-10-25 | 2024-08-23 | 2024-04-19 |
| 审计意见(境内) | 标准无保留意见 | | | |